VITL never pitched SignalFire directly, but the startup's rapid growth caught the venture firm's attention. That interest translated into a $7.5 million Series A funding round, announced this week. The Nashville-based company is solving a problem that sounds like it belongs in 1995, not 2026: many healthcare providers still manage prescriptions using faxes and phone calls.
VITL, an 18-month-old startup, claims to be solving one of the sector's biggest tech bottlenecks by building an e-prescribing platform tailored for cash-pay medical businesses. The real-world problem is straightforward. The number of med-spas, weight loss clinics, and concierge practices where patients pay a membership fee for direct, often same-day access to physicians, has exploded in recent years. But while patients pay for these services out-of-pocket, providers still often rely on software built for traditional, insurance-based care.
Founder and CEO Charlie Jordan built the company after realizing just how much time medical providers spend managing prescriptions for treatments not covered by insurance. Many providers still rely on faxes or phone calls to send prescriptions to compounding pharmacies, which create custom medications to order, often without knowing the final cost to the patient or how long the order will take to fill. VITL's platform fixes this by connecting clinics to a nationwide network of compounding pharmacies, offering real-time price comparisons and Amazon-style order tracking.
The competitive landscape matters here. VITL competes partly with Surescripts, the industry's e-prescribing pioneer, and with boutique clinic platforms like Jane Software. What sets VITL apart from these competitors is its singular focus on the workflow requirements of the cash-pay medical sector. Most established e-prescribing infrastructure was designed for traditional insurance-based healthcare, where the economics and workflows are fundamentally different.
Scale presents the bigger opportunity and the bigger risk. 630 customers represents just a fraction of a market that includes tens of thousands of clinics across the U.S. As interest in GLP-1s (the class of drugs that includes Ozempic and Wegovy), peptides, and aesthetic procedures like Botox grows more mainstream, the number of cash-pay healthcare businesses is only set to expand. That expansion creates both upside for VITL and a cautionary tale about market infrastructure outpacing regulatory oversight.
This funding round reveals something worth thinking about beyond the startup headline: healthcare markets move faster than the systems built to support them. When demand spikes, providers adapt with what's available, not what's ideal. SignalFire recognised something investors often miss in hype-driven sectors like GLP-1: the unglamorous infrastructure problems tend to be the most durable businesses. Nobody wants to use fax machines to manage prescriptions, but fixing that problem isn't sexy. It's just necessary.